Bovine Mastitis Market Analysis & Forecast: 2025-2032

Global Bovine Mastitis Market Analysis & Forecast: 2025-2032

Global Bovine Mastitis Market size is estimated to be valued at USD 1,564.6 Mn  in 2025 and is expected to reach USD 2,260.9 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 23.4% from 2025 to 2032.

Key Takeaways

• By Type, the Clinical Mastitis segment is projected to dominate the Bovine Mastitis Market with a 55.0% revenue share in 2025, driven by its higher prevalence, visible symptoms, and increased demand for immediate veterinary intervention.
• By Region, North America is expected to lead the global Bovine Mastitis Market outlook with a projected share of 39.20% in 2025, supported by well-established dairy infrastructure, high awareness among farmers, and widespread adoption of advanced mastitis treatment solutions.

Market Overview

Bovine mastitis is a medical condition that is common in dairy cows. It refers to the inflammation of mammary gland and udder tissue. The disease can cause harm to the milk-secreting tissues in cows, which is one of the main reasons, it is considered as a dangerous condition. The increased global incidence of bovine mastitis is expected to have a positive impact on the overall market growth over the forecast period. When mastitis is discovered, the first aid is to apply ice cubes to the udder surface. Infected milk from diseased teats should be drained three times a day and disposed properly. To ensure hygienic disposal, a 5% phenol solution can be added to the infected milk.

Current Events and Its Impact on the Bovine Mastitis Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Pipeline Analysis

• No specific pipeline candidates or clinical trial details for bovine mastitis treatments are publicly disclosed as of 2025, including molecule names, phases, or sponsors.
• Emerging therapeutic research highlights bacteriophage therapy as a promising antibiotic alternative; a recent study identified three novel phages effective against major mastitis pathogens such as Staphylococcus aureus and Escherichia coli.
• The bovine mastitis treatment market, valued at $2 billion in 2024, is expected to grow to $3.7 billion by 2034, driven by rising dairy demand and advances in intramammary infusion therapies.
• Traditional antibiotics like penicillin and cephalosporin remain widely used, with ongoing efforts to mitigate antibiotic resistance.
• Industry players such as MSD Animal Health have hinted at undisclosed pipeline candidates, but regulatory approval timelines are uncertain.
• Academic research, including studies at Virginia Tech, focuses on improving mastitis detection and management through somatic cell analysis.
• Comprehensive pipeline insights require access to proprietary clinical trial registries or regulatory filings beyond publicly available sources.

Patent Landscape

• There is a significant rise in patents targeting antimicrobial peptides, reflecting their growing importance as alternatives to traditional antibiotics.
• Vaccine formulation patents are evolving to improve efficacy and delivery methods, addressing emerging infectious diseases.
• Diagnostic technology patents increasingly emphasize rapid, precise, and point-of-care solutions, enhancing early detection capabilities.
• Recent innovations focus on biosensor integration, enabling continuous, real-time infection monitoring and personalized healthcare.
• Patent filings remain dominant in North America and Europe, driven by strong R&D infrastructure and regulatory support.
• Asia-Pacific biotech firms are rapidly increasing patent activity, fueled by expanding markets, government incentives, and advancing biotech ecosystems.
• The global shift in patent filings indicates a competitive landscape focused on next-generation antimicrobial and diagnostic solutions.

Reimbursement Scenario

Reimbursement for bovine mastitis treatment and management varies significantly across regions, influenced by differing codes, regulations, government programs, and insurance plans.

Codes and Regulations:

• Diagnosis and treatment are categorized under various International Classification of Diseases (ICD) codes such as ICD-10-CM N61 (inflammatory disorders of breast) and related codes.
• Treatment procedures utilize Current Procedural Terminology (CPT) codes like CPT 19000 (puncture aspiration of cyst of breast) and CPT 19081 (breast biopsy with localization device placement).

Processes and Agencies:

• Veterinarians are the primary service providers diagnosing and treating bovine mastitis; they submit reimbursement claims to insurers or government bodies.
• Key regulatory agencies include the United States Department of Agriculture (USDA), European Medicines Agency (EMA), and Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF), which oversee veterinary health standards and reimbursement frameworks.
• Private insurance companies provide livestock insurance policies covering bovine mastitis, with farmers paying premiums and receiving claim-based reimbursements.

Regional Insurance Plans and Coverage:

• United States:
  The Livestock Gross Margin for Dairy (LGM-Dairy) program protects farmers against financial losses by covering margin risks between milk prices and feed costs. Reimbursements depend on farmer-selected deductibles, with the total premium reaching $47.5 million in 2020.
• European Union:
  The European Agricultural Fund for Rural Development (EAFRD) supports animal health management, including mastitis control. Funding and reimbursement levels vary by country and program, with a €96.2 billion allocation for rural development in 2020.
• Australia:
  Dairy Australia's Countdown 2020 program supports mastitis control efforts, offering farmers up to 50% reimbursement on related costs (capped at AUD 2,000 per farm). Annual spending on mastitis control approximates AUD 150 million.
• New Zealand:
  DairyNZ’s SmartSAMM initiative provides tools for mastitis management, complemented by funding via the Sustainable Farming Fund. The estimated annual cost of mastitis in New Zealand stands at NZD 280 million.

Prescribers’ Preferences for Bovine Mastitis Treatment

• Bovine mastitis treatment preferences vary by disease stage and severity. Intramammary antibiotics are the primary choice, delivering high drug concentrations directly to infected udder quarters. Common drugs include ceftiofur, pirlimycin, and cloxacillin. Systemic antibiotics are used in severe or multi-quarter infections, with agents like injectable ceftiofur and florfenicol.
• Supportive therapies such as NSAIDs (e.g., flunixin meglumine, ketoprofen) reduce inflammation and pain, while fluid therapy helps in severe cases. Management practices like increased milking frequency and strict hygiene are crucial to control infection spread.
• Treatment differs by stage: subclinical cases focus on intramammary antibiotics and teat sealants; clinical cases combine intramammary and systemic antibiotics with NSAIDs; chronic mastitis may require extended antibiotic use or culling.
• Prescribers consider antibiotic susceptibility, milk withdrawal times, herd health, and cost when selecting treatments. The veterinarian-client relationship also plays a vital role in treatment adherence and management decisions.

Segmental Analysis

To learn more about this report, Request sample copy

Bovine Mastitis Market Insights, By Type

The Clinical Mastitis segment is projected to dominate the bovine mastitis market in 2025, accounting for 55.0% of the total Bovine Mastitis Market growth revenue. This dominance is attributed to the clear and visible symptoms associated with clinical mastitis, such as inflammation, swelling of the udder, and abnormal milk. These symptoms prompt immediate diagnosis and treatment, contributing to higher detection rates and increased product demand.

Clinical mastitis requires urgent veterinary attention and often involves the use of intramammary antibiotics, anti-inflammatory drugs, and supportive therapies—further boosting market value in this segment. The economic impact of untreated clinical mastitis, including reduced milk yield, discarded milk, and veterinary costs, compels dairy farmers to invest in early treatment solutions.

As global dairy producers place greater emphasis on milk quality and herd health, the clinical mastitis segment is likely to benefit from advancements in rapid diagnostics and therapeutic options. Moreover, increased awareness campaigns and farmer training programs are encouraging prompt identification and intervention, reinforcing the market share held by this segment.

In contrast, sub-clinical mastitis, though more prevalent, remains underdiagnosed due to the absence of visible symptoms. However, it continues to be a latent concern and presents an opportunity for growth in surveillance and preventative solutions.

Regional Insights

To learn more about this report, Request sample copy

North America Bovine Mastitis Market Analysis and Trends

North America is projected to lead the global bovine mastitis market forecast, contributing an estimated 39.20% of total revenue in 2025. This dominance is supported by the region’s advanced veterinary infrastructure, high standards of dairy hygiene, and widespread adoption of preventive care measures across dairy farms in the U.S. and Canada.

Veterinary pharmaceutical companies in North America are at the forefront of developing innovative mastitis therapies, including intramammary antibiotics and diagnostic kits. In addition, government-backed milk quality programs and farm-level disease monitoring systems have driven early intervention and reduced economic losses due to mastitis. These developments collectively reinforce North America's position as the dominant region in the market.

Asia Pacific Bovine Mastitis Market Analysis and Trends

Asia Pacific is expected to emerge as the fastest-growing regional bovine mastitis market growth by 2025. Countries such as India, China, and Australia are witnessing significant growth in their dairy sectors due to rising milk consumption, supportive government policies, and commercialization of livestock farming.

India and China, in particular, are investing heavily in dairy infrastructure modernization and farmer education programs that highlight the importance of mastitis prevention and control. Increasing adoption of veterinary services and greater availability of affordable mastitis treatment options are accelerating market expansion across the region. Moreover, Australia’s robust dairy exports and commitment to animal health standards contribute to regional growth.

Dominating Countries in the Bovine Mastitis Market

United States Bovine Mastitis Market Analysis and Trends

The United States stands out as the largest contributor to the North American bovine mastitis market. Its dominance is fueled by large-scale dairy farms, early adoption of precision livestock farming technologies, and comprehensive veterinary healthcare systems. Federal and state-level programs promoting milk safety and disease control play a critical role in reducing the incidence of mastitis, thereby supporting market growth.

India Bovine Mastitis Market Analysis and Trends

India is poised to be a key driver of growth in the Asia Pacific bovine mastitis market. As the world’s largest milk producer, India faces a high prevalence of mastitis, which has prompted both public and private initiatives aimed at disease control. Ongoing improvements in veterinary infrastructure, farmer training programs, and increasing access to effective mastitis treatments are helping to improve herd health and milk productivity across the country.

Market Report Scope

Rising incidence of bovine mastitis is expected to drive the market growth

The increasing incidence of bovine mastitis is expected to drive the market growth over the forecast period For instance, the global incidence of bovine mastitis ranges between 0 and 200 cows, according to the Cornell University College of Veterinary Medicine.

Furthermore, the University of Glasgow estimates that bovine mastitis will cost between US$19.7 billion and $ 30 billion in annual healthcare costs, globally. Moreover, rising prevalence of bovine mastitis infections during the dry season, as well as the increased benefits of non-antibiotic intramammary products such as Teat Sealants in preventing new intramammary infections during the dry season, are expected to drive the market growth.

Increasing product launches for animal healthcare is expected to boost the market growth

Cows are more susceptible to mastitis during dry off due to the environmental and physiological changes they go through. Because keratin plug growth changes throughout the dry period, a cow's natural barrier against new intramammary infections, pathogen risk is higher. When dry cows are exposed to high levels of environmental infections, National Mastitis Council's Recommended Mastitis Control Program recommends using a teat sealant.

For instance, in February 2020 Merck & Co. Inc. announced the launch of Shut Out, a sterile, antibiotic-free barrier and a novel teat sealant solution. The product is intended to be used prior to dry off, in order to help avoid intramammary infections.

Analyst Viewpoint

• The global bovine mastitis market is witnessing strong growth, primarily fueled by the rising global demand for dairy products and the corresponding increase in dairy cattle populations.
• Heightened awareness among dairy farmers regarding the economic impact of mastitis on milk yield and animal health is accelerating the adoption of diagnostic and treatment solutions.
• Market expansion is somewhat restrained by the high costs of treatment and limited awareness among small-scale farmers in developing regions.
• Regulatory restrictions on antibiotic use in food-producing animals pose challenges to the adoption of certain therapeutics
• Asia-Pacific is emerging as a key growth region, led by expanding dairy industries, rising consumer demand, and growing awareness of animal health practices, especially in India and China.
• Innovation in cost-effective, rapid-action diagnostics and alternative treatments is expected to create new growth avenues and help overcome existing limitations.

Recent Developments

• In May 2025, Elanco Animal Health partnered with a European dairy consortium to pilot a mastitis prevention program integrating vaccines, real-time sensor data, and precision treatment protocols.
• In April 2025, Boehringer Ingelheim unveiled a new on-farm diagnostic tool for early detection of bovine mastitis, aimed at improving herd health management and reducing antibiotic misuse.
• In February 2025, Zoetis Inc. launched MastiSure™ Rapid, an advanced intramammary therapy featuring fast-acting antibiotics and reduced milk withdrawal periods, enhancing treatment outcomes for clinical mastitis.

Key Players

Major players operating in the global bovine mastitis market include Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd.

Market Segmentation

• Global Bovine Mastitis Market, By Type:
  • Clinical Mastitis
  • Sub-clinical Mastitis
• Global Bovine Mastitis Market, By Product:
  • Antibiotics
  • Vaccines
  • Pain Killers
  • Others
• Global Bovine Mastitis Market, By Route of Administration:
  • Intra-mammary
  • Systemic
• Global Bovine Mastitis Market, By Therapy:
  • Lactating Period
  • Dry Period
    • Antibiotics
    • Teat Sealants
• Global Bovine Mastitis Market, By End User:
  • Veterinary Centers
  • Hospital
  • Clinics
  • Others
• Global Bovine Mastitis Market, By Region:       
  • North America
    
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Zoetis
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Elanco
  • Ceva
  • West Way Health
  • Norbrook
  • DeLaval
  • ImmuCell Corporation
  • Advanced Animal Diagnostics
  • Nimrod Veterinary Products Ltd

Sources

Primary Research Interviews:

• Veterinarians
• Dairy farmers
• Animal health company representatives
• Pharmaceutical company representatives
• Others

Databases:

• PubMed
• ScienceDirect
• Web of Science
• Scopus
• Others

Magazines:

• Dairy Herd Management
• Progressive Dairy
• Bovine Veterinarian
• Hoard's Dairyman
• Others

Journals:

• Journal of Dairy Science
• Veterinary Microbiology
• Preventive Veterinary Medicine
• Others

Newspapers:

• Dairy Star
• Farmshine
• The Cattle Site News
• Dairy Global
• Others

Associations:

• National Mastitis Council
• American Dairy Science Association
• World Association for Buiatrics
• International Dairy Federation
• Others

Public Domain Sources:

• United States Department of Agriculture (USDA)
• World Health Organization (WHO)
• Food and Agriculture Organization (FAO)
• National Center for Biotechnology Information (NCBI)
• Others

Proprietary Elements:

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years